{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:02Z","timestamp":1790916962336,"version":"4.1.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Multiple prostate-specific membrane antigen (PSMA) PET tracers are used for patient selection in radioligand therapy (RLT). This study compared treatment response to RLT across different PSMA tracers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed patients who underwent Lu-177 PSMA-617 RLT with baseline imaging using either Ga-68 PSMA-11 or F-18 DCFPyL PET. PET parameters were measured, including SUV\n                      <jats:sub>mean<\/jats:sub>\n                      , SUV\n                      <jats:sub>max<\/jats:sub>\n                      , and total tumor volume (TTV). Univariable and multivariable logistic regression analyses were performed to evaluate factors associated with PSA50 response, and Cox proportional hazards regression analyses were performed to evaluate factors associated with overall survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 140 patients analyzed (Ga-68 PSMA-11: n=51; F-18 DCFPyL: n=89), SUV\n                      <jats:sub>max<\/jats:sub>\n                      and SUV\n                      <jats:sub>mean<\/jats:sub>\n                      did not differ significantly between groups; however, TTV was significantly higher in the Ga-68 PSMA-11 group (p=0.038). In multivariable analysis adjusted for age, baseline PSA, PET tracer type, SUVmean, and log-transformed TTV, PET tracer type was not significantly associated with PSA50 response (OR, 1.318; 95% CI, 0.585\u20132.970; p=0.505), whereas higher SUVmean was associated with greater odds of PSA50 response (OR, 1.285; 95% CI, 1.126\u20131.466; p&amp;lt;0.001). Overall survival did not differ significantly between tracer groups (HR, 0.760; 95% CI, 0.507\u20131.138; p=0.183), with median overall survival of 8.4 and 12.6 months. In multivariable analysis, PET tracer type was not significantly associated with overall survival (HR, 0.736; 95% CI, 0.475\u20131.139; p=0.168), whereas higher SUVmean was associated with a lower risk of death (HR, 0.886; 95% CI, 0.825\u20130.950; p&amp;lt;0.001) and higher log-transformed TTV was associated with a higher risk of death (HR, 1.415; 95% CI, 1.194\u20131.678; p&amp;lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      PET tracer type was not significantly associated with PSA50 response or overall survival following RLT. Higher SUV\n                      <jats:sub>mean<\/jats:sub>\n                      was associated with greater odds of PSA50 response and a lower risk of death, whereas higher TTV was associated with overall survival.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1932583","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:41:47Z","timestamp":1790916107000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of treatment response to PSMA radioligand therapy using Ga-68 PSMA-11 and F-18 DCFPyL PET imaging"],"prefix":"10.3389","volume":"16","author":[{"given":"Chae Moon","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco","place":["San Francisco, CA, United States"]},{"name":"Department of Nuclear Medicine, Kyungpook National University","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuzar","family":"Moradi Tuchayi","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Abtahi","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stellamaris","family":"Nwihim","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surekha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco","place":["San Francisco, CA, United States"]},{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: Results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): Secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382582","article-title":"Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection","volume":"14","author":"Yadav","year":"2024","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014","article-title":"Development of a visually calculated SUVmean (HIT Score) on screening PSMA PET\/CT to predict treatment response to 177Lu-PSMA therapy: Comparison with quantitative SUVmean and patient outcomes","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270804","article-title":"Prognostic value of initial imaging and PSA change with [177Lu]Lu-PSMA-617 radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer: A ProsTIC Registry analysis","volume":"66","author":"Chen","year":"2025","journal-title":"J Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(26)00016-1","article-title":"New prostate cancer risk groups by PSMA-PET (PPP3): An international, retrospective, registry-based cohort study","volume":"27","author":"Karpinski","year":"2026","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1932583\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:41:54Z","timestamp":1790916114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1932583\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":13,"alternative-id":["10.3389\/fonc.2026.1932583"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1932583","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1932583"}}